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In the spring of 2012, the Czech Society of Cardiology and Czech Hypertension Society issued
a joint expert consensus statement on catheter-based renal denervation (RDN) in the Czech
Republic. On the basis of new information from the Symplicity HTN-3, PRAGUE-15 and other
studies, there is no reason to introduce RDN into clinical practice. New modalities for RDN,
such as radiofrequency ablation, are investigated.
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. In the spring of 2012, the Czech Society of Cardiology (CSC) and
Czech Hypertension Society (CHS) issued a joint expert
consensus statement on catheter-based renal denervation
(RDN) in the Czech Republic [1]. By that time, only one trial
with patients randomized to either treatment with RDN or
conservative therapy – Symplicity HTN-2 – had been published
[2]. While documenting a decrease in blood pressure (BP) in the
intervention group, the study drew criticism for a variety of
shortcomings including, most importantly, a small number of
patients (with RDN performed in 52 individuals) and inclusion
criteria: ambulatory BP monitoring (ABPM) had not been
performed consistently, the issue of patient compliance to* Corresponding author . Tel.: +420 377 402 439; fax: +420 377 402 374.          
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0010-8650/# 2015 The Czech Society of Cardiology. Published by Elsedrug therapy was completely disregarded, and it was unclear
whether the patients had been adequately examined to rule
out secondary hypertension. As a result, the Czech position on
indicating RDN was a rather cautious one.
The results of the landmark Symplicity HTN-3 trial were
published in 2014 [3]; it is to date the largest prospective
randomized study of RDN in patients with resistant hyperten-
sion. Its primary aims were to assess changes in ofﬁce systolic
BP measured at 6 months post-RDN and to determine the
incidence of serious complications within the ﬁrst post-
procedural month. The mean age of the 535 enrolled patients
was 57 years, with women making up 39% of the study group.vier Sp. z o.o. All rights reserved..
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value measured by ABPM being 159 mmHg. The patients
received stable drug therapy including diuretics (99.8%), beta-
blockers (86%), angiotensin-converting enzyme inhibitors
(46%), angiotensin receptor blockers (51%), and mineralocorti-
coid receptor antagonists (25%). One in three patients were
randomized to a sham procedure involving renal arteriogra-
phy, yet without RDN; this group served as a control. The
remaining two-thirds of patients (364 individuals) did receive
RDN. The effect of RDN on BP levels in this controlled and well-
designed study was not superior to that of the sham
procedure. The mean decrease in systolic BP at 6 months
was 14.1  24.0 mmHg post-RDN compared with 11.7
 26.0 mm Hg after the sham procedure ( p = 0.26). The mean
decrease in systolic BP in 24-h ABPM after RDN was 6.8
 15.1 mmHg compared with 4.8  17.3 mmHg after the sham
procedure; the mean difference of 2 mmHg again did not reach
statistical signiﬁcance possibly documenting RDN superiority
( p = 0.98), both in daytime systolic BP ( p = 0.52) and nighttime
systolic BP ( p = 0.06), with no signiﬁcant difference also found
in 24-h mean heart rate between RDN and non-RDN patients
( p = 0.94). Likewise, no signiﬁcant difference was observed in
the incidence of serious complications.
The interpretation of the above data varies with some
speculating that, e.g., in some of the 87 participating centers,
RDN was performed using an improper technique so the
failure was due to inadequate denervation. While it is difﬁcult
to check this in retrospect, it is clear that the results of
Symplicity HTN-3 are completely negative and that there is
currently no rationale for introducing RDN to routine clinical
practice.
This conclusion is supported by recent outcomes of RDN in
10 European hypertension centers including one based in the
General University Hospital in Prague [4]. Blood pressure
normalization post-RDN was obtained in only a minority of
cases. Ambulatory BP monitoring conﬁrmed only a small BP
reduction after RDN, which may have included the effect of
regression to mean [4].
In the Czech Republic, the RDN technique was introduced
in several centers, with the procedures performed mostly as
part of clinical trials, the most important one of which was the
PRAGUE-15 study [5]. This open-label prospective randomized
multicenter study compared the effect of RDN (using Sympli-
city catheters) with intensiﬁed drug therapy including spir-
onolactone (if tolerated) in patients with resistant
hypertension. Prior to their inclusion in the study, all patients
had a thorough assessment to rule out secondary hyperten-
sion, and their good compliance to treatment was veriﬁed by
measuring serum levels of antihypertensive drugs. The
primary endpoint was change in systolic and diastolic BP
measured by 24-h ABPM at 6 months of therapy. PRAGUE-15
was stopped prematurely after the publication of the results of
SYMPLICITY-HTN 3. Overall, PRAGUE-15 included 106 individ-
uals (52 receiving RDN and 54 conservative therapy only). The
results of PRAGUE-15 showed a comparable decrease in 24-h
BP following RDN and intensiﬁed antihypertensive therapy.
In a recent small Norwegian study, patients with resistant
hypertension conﬁrmed by ABPM and veriﬁed compliance
(taking antihypertensives in the presence of a healthcare
professional) were randomized to groups receiving either RDNusing Symplicity catheters (n = 9) or intensiﬁed drug therapy
(n = 10) [6]. The study was terminated prematurely due to a
more signiﬁcant BP reduction in conservatively treated
patients. However, an obvious weakness of the study was
the small number of subjects enrolled.
As documented by a recent Dutch study, RDN results in
major variability in the antihypertensive effect [7]. While some
patients respond with a mild decrease in BP, in others the BP
level either remains unchanged or even increases. The
inadequate BP reduction post-RDN could be explained by
the absence of changes in renin levels.
The ﬁrst large study using a different technology, i.e., the
multi-electrode radiofrequency ablation EnligHTN system was
published this year [8]. The 12-month study was designed to
follow 46 patients with resistant hypertension after RDN.
During follow-up, there was a marked decrease in systolic BP,
as measured in the ofﬁce (27 mmHg), by ABPM (11 mmHg)
and at home (11 mmHg), and reasonable safety over the
above mentioned period of time was documented. While the
procedure seems to be technically acceptable, the study
did not include a control group; hence, again, additional data
are yet to be awaited. At present, other techniques of
denervation – particularly use of ultrasound – are currently
being investigated; however, data from controlled studies are
still unavailable.
The 2012 expert consensus statement of the Czech Society
of Cardiology and the Czech Hypertension Society [1] notes
that ‘‘until other and/or larger randomized studies have
conﬁrmed (or failed to conﬁrm) the promising results of initial
studies, RDN procedures can only be part of certain research
protocols approved by ethics committees. (. . ..) It is unethical
to advertise this technique already today (at the beginning of
2012) as standard part of treatment of hypertensive individu-
als. Every patient should be advised that RDN is still an
investigational procedure.’’ At present, i.e. in the second half
of the year 2014, this position remains unchanged and the
results of Symplicity HTN-3 and a number of other studies
support the above position whereby RDN should only be
performed as an investigational procedure. It should also be
taken into account that resistant hypertension requires a most
cautious clinical approach, in particular, an analysis of
previous treatment, ABPM measurement, veriﬁcation of
adherence to drug therapy, and exclusion of secondary
hypertension. It is thus clear that RDN should only be
undertaken in specialized hypertension centers capable of
performing the necessary pre-selection of patients [9,10]. Only
in a minority of patients with originally resistant hypertension
will a thorough assessment conﬁrm true resistance to drug
therapy [9,10]. It is not appropriate to consider any type of
interventional treatment unless such a thorough assessment
has been performed. Regarding further research into RDN, it
would seem reasonable that future study protocols do not just
repeat previously explored avenues but search for novel
approaches instead, either in terms of technology (more
sophisticated ablation techniques) or in terms of indication as,
besides resistant hypertension, there are other conditions
associated with increased sympathetic activity such as sleep
apnea, recurrent heart failure, or insulin resistance. Preclinical
testing of new approaches should continue, and clinical trials
should undergo extremely careful ethical scrutiny.
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the recently published data obtained using optical coherent
tomography with high resolution (10–15 mm) have shown that
RDN is followed by morphological alterations in the renal
vascular bed; which remain undetected by routine angiogra-
phy [11]. These are diffuse alterations in the renal artery
including endothelial edema; spasms; narrowing of the
arterial lumen; and thrombus formation at ablation site.
The extent to which these alterations are relevant in the long
run is not known at the moment.
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